tetano
Editor, Senior Moderator
Genes Dis
. 2021 Dec 3.
doi: 10.1016/j.gendis.2021.11.007. Online ahead of print.
Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
Jie Hu[SUP] 1 [/SUP], Xiao-Yu Wei[SUP] 2 [/SUP], Jin Xiang[SUP] 1 [/SUP], Pai Peng[SUP] 1 [/SUP], Feng-Li Xu[SUP] 1 [/SUP], Kang Wu[SUP] 1 [/SUP], Fei-Yang Luo[SUP] 3 [/SUP], Ai-Shun Jin[SUP] 3 [/SUP], Liang Fang[SUP] 2 [/SUP], Bei-Zhong Liu[SUP] 2 [/SUP], Kai Wang[SUP] 1 [/SUP], Ni Tang[SUP] 1 [/SUP], Ai-Long Huang[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody therapeutics. However, multiple variants of SARS-CoV-2 have emerged, which may potentially compromise vaccine effectiveness. Using a pseudovirus-based assay, we evaluated SARS-CoV-2 cell entry mediated by the viral Spike B.1.617 and B.1.1.7 variants. We also compared the neutralization ability of monoclonal antibodies from convalescent sera and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, compared to D614G and B.1.1.7 variants, B.1.617 shows enhanced viral entry and membrane fusion, as well as more resistant to antibody neutralization. These findings have important implications for understanding viral infectivity and for immunization policy against SARS-CoV-2 variants.
Keywords: Coronavirus; Immune escape; Mutation; Neutralizing antibodies; SARS-CoV-2; Vaccine; Viral entry.
. 2021 Dec 3.
doi: 10.1016/j.gendis.2021.11.007. Online ahead of print.
Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
Jie Hu[SUP] 1 [/SUP], Xiao-Yu Wei[SUP] 2 [/SUP], Jin Xiang[SUP] 1 [/SUP], Pai Peng[SUP] 1 [/SUP], Feng-Li Xu[SUP] 1 [/SUP], Kang Wu[SUP] 1 [/SUP], Fei-Yang Luo[SUP] 3 [/SUP], Ai-Shun Jin[SUP] 3 [/SUP], Liang Fang[SUP] 2 [/SUP], Bei-Zhong Liu[SUP] 2 [/SUP], Kai Wang[SUP] 1 [/SUP], Ni Tang[SUP] 1 [/SUP], Ai-Long Huang[SUP] 1 [/SUP]
Affiliations
- PMID: 34877393
- PMCID: PMC8639289
- DOI: 10.1016/j.gendis.2021.11.007
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody therapeutics. However, multiple variants of SARS-CoV-2 have emerged, which may potentially compromise vaccine effectiveness. Using a pseudovirus-based assay, we evaluated SARS-CoV-2 cell entry mediated by the viral Spike B.1.617 and B.1.1.7 variants. We also compared the neutralization ability of monoclonal antibodies from convalescent sera and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, compared to D614G and B.1.1.7 variants, B.1.617 shows enhanced viral entry and membrane fusion, as well as more resistant to antibody neutralization. These findings have important implications for understanding viral infectivity and for immunization policy against SARS-CoV-2 variants.
Keywords: Coronavirus; Immune escape; Mutation; Neutralizing antibodies; SARS-CoV-2; Vaccine; Viral entry.